Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice

Journal of Pathology

Volumn 210, Issue 4, 2006, Pages 469-477

  Nomoto, K ^a   Tsuneyama, K ^a   Abdel Aziz, H O ^a   Takahashi, H ^a   Murai, Y ^a   Cui, Z G ^a   Fujimoto, M ^a   Kato, I ^a   Hiraga, K ^a   Hsu, D K ^b   Liu, F T ^b   Takano, Y ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Advanced glycation end products (AGE); Non alcoholic fatty liver disease (NAFLD); Non alcoholic steatohepatitis (NASH); Peroxisome proliferator activated receptor (PPAR ); Receptor for AGE (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; GALECTIN 3; LIPID PEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; KNOCKOUT MOUSE; LIVER HISTOLOGY; LIVER LEVEL; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; WILD TYPE;

ALANINE TRANSAMINASE; ANIMALS; BODY WEIGHT; FATTY LIVER; GALECTIN 3; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; ORGAN SIZE; PPAR GAMMA; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 33751529246     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2065     Document Type: Article

References (48)

1. Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol 1996;156:3939-3944.
2. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996;56:4530-4534.
3. Ochieng J, Warfield P, Green-Jarvis B, Fentie I. Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J Cell Biochem 1999;75:505-514.
4. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 2002;168:1813-1822.
5. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 2005;26:309-318.
6. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000;165:2156-2164.
7. Dagher SF, Wang JL, Patterson RJ. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 1995;92:1213-1217.
8. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996;93:6737-6742.
9. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634-646.
10. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001;280:1183-1188.
11. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992;267:14987-14997.
12. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, et al. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann N Y Acad Sci 2000;902:163-170; discussion 170-172.
13. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268.
14. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004;18:1773-1775.
15. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 2004;101:11767-11772.
16. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481-1490.
17. Lander HM, Tauras JM, Ogiste IS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-17814.
18. Fowlis D, Colnot C, Ripoche MA, Poirier F. Galectin-3 is expressed in the notochord, developing bones, and skin of the postimplantation mouse embryo. Dev Dyn 1995;203:241-251.
19. Van den Brule FA, Fernandez PL, Buicu C, Liu FT, Jackers P, Lambotte R, et al. Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 1997;209:399-405.
20. Cerra RF, Gitt MA, Barondes SH. Three soluble rat beta-galactoside-binding lectins. J Biol Chem 1985;260:10474-10477.
21. 4. Biochem Biophys Res Commun 2001;280:1077-1084.
22. Flotte TJ, Springer TA, Thorbecke GJ. Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. Am J Pathol 1983;111:112-124.
23. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999;81:519-526.
24. Maeda N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, et al. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem 2003;278:18938-18944.
25. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006;103:5060-5065.
26. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-723.
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
28. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
29. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
30. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
31. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372.
32. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998;114:842-845.
33. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
34. Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000;156:1073-1083.
35. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 2004;17:1141-1149.
36. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004;39:422-432.
37. Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005;201:473-484.
38. Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher D. Hepatic expression of galectin-3 and RAGE in patients with liver disease. J Clin Pathol published online 14 Jun 2006.
39. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
40. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, et al. Beta 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252.
41. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:571-582.
42. Takedo A, Yasuda T, Miyata T, Mizuno K, Li M, Yoneyama S, et al. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 1996;221:17-20.
43. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004;122:461-467.
44. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005;288:E1195-E1205.
45. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 2003;278:498-505.
46. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003;111:737-747.
47. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-34276.
48. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998;273:5678-5684.